Patents by Inventor Guity P. Balow

Guity P. Balow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ?-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom
    Patent number: 8119680
    Abstract: Novel compounds, compositions, and kits are provided. Methods of modulating A? levels, and methods of treating a disease associated with aberrant A? levels are also provided.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: February 21, 2012
    Assignee: Neurogenetic Pharmaceuticals, Inc.
    Inventors: Soan Cheng, Daniel D Comer, Long Mao, Guity P Balow, David Pleynet
  • Compounds and uses thereof in modulating amyloid ?
    Patent number: 8017629
    Abstract: Novel compounds, compositions, and kits are provided. Methods of modulating A? levels, and methods of treating a disease associated with aberrant A? levels are also provided.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: September 13, 2011
    Assignee: Neurogenetic Pharmaceuticals, Inc.
    Inventors: Soan Cheng, Daniel D. Comer, Long Mao, Guity P. Balow, David Pleynet
  • ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM
    Publication number: 20100331551
    Abstract: Novel compounds, compositions, and kits are provided. Methods of modulating A? levels, and methods of treating a disease associated with aberrant A? levels are also provided.
    Type: Application
    Filed: September 3, 2010
    Publication date: December 30, 2010
    Inventors: Soan Cheng, Daniel D. Comer, Long Mao, Guity P. Balow, David Pleynet
  • COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA
    Publication number: 20100324032
    Abstract: Novel compounds, compositions, and kits are provided. Methods of modulating A? levels, and methods of treating a disease associated with aberrant A? levels are also provided.
    Type: Application
    Filed: August 23, 2010
    Publication date: December 23, 2010
    Inventors: Soan Cheng, Daniel D. Comer, Long Mao, Guity P. Balow, David Pleynet
  • ?-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom
    Patent number: 7799808
    Abstract: Novel compounds, compositions, and kits are provided. Methods of modulating A? levels, and methods of treating a disease associated with aberrant A? levels are also provided.
    Type: Grant
    Filed: June 19, 2007
    Date of Patent: September 21, 2010
    Assignee: Neurogenetic Pharmaceuticals, Inc.
    Inventors: Soan Cheng, Daniel D. Comer, Long Mao, Guity P. Balow, David Pleynet
  • Compounds and uses thereof in modulating amyloid beta
    Patent number: 7781442
    Abstract: Novel compounds, compositions, and kits are provided. Methods of modulating A? levels, and methods of treating a disease associated with aberrant A? levels are also provided.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: August 24, 2010
    Assignee: Neurogenetic Pharmaceuticals, Inc.
    Inventors: Soan Cheng, Daniel D. Comer, Long Mao, Guity P. Balow, David Pleynet
  • Compounds and uses thereof in modulating amyloid beta
    Patent number: 7244739
    Abstract: Novel compounds, compositions, and kits are provided. Methods of modulating A? levels, and methods of treating a disease associated with aberrant A? levels are also provided.
    Type: Grant
    Filed: May 14, 2004
    Date of Patent: July 17, 2007
    Assignee: Torreypines Therapeutics, Inc.
    Inventors: Soan Cheng, Daniel D. Comer, Long Mao, Guity P. Balow, David Pleynet
  • Sugar-modified 7-deaza-7-substituted oligonucleotides
    Patent number: 6093807
    Abstract: Functionalized nucleomonomers and oligonucleotides are provided which have increased nuclease resistance and enhanced binding affinity to target DNA or RNA molecules. The oligonucleotides of the present invention comprise at least one 7-deaza-7-iodo-2'-substituted purine, herein referred to as a functionalized nucleomonomer. A preferred 2' substituent on the sugar moiety is a 2'-O-alkoxy alkyl group. More preferably, the 2'-substituent is 2'--O--CH.sub.2 --CH.sub.2 --O--CH.sub.3 (or 2'-methoxyethoxy). Such oligonucleotides are useful as therapeutics for modulating protein expression in organisms and treating disease states susceptible to oligonucleotide therapeutics. Such oligonucleotides are also useful as diagnostics for the diagnosis and detection of disease states, and as research reagents.
    Type: Grant
    Filed: March 19, 1999
    Date of Patent: July 25, 2000
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Guity P. Balow, Oscar L. Acevedo, Phillip Dan Cook